Intravenous N-Acetylcysteine for Prevention of Contrast-Induced Nephropathy: A Meta-Analysis of Randomized, Controlled Trials

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Sun, Zikai ^a   Fu, Qiang ^a   Cao, Longxing ^a   Jin, Wen ^b   Cheng, LingLing ^a   Li, Zhiliang ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG SECOND PROVINCIAL GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM; HYDROCORTISONE;

ARTICLE; CAUSE OF DEATH; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; HOT FLUSH; HUMAN; KIDNEY FAILURE; LENGTH OF STAY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; META ANALYSIS; PREVENTION STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ACETYLCYSTEINE; ADMINISTRATION, INTRAVENOUS; CONTRAST MEDIA; HUMANS; KIDNEY DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84873856342     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055124     Document Type: Article

References (57)

1. Parfrey P, (2005) The clinical epidemiology of contrast-induced nephropathy. Cardiovasc Intervent Radiol 28Suppl 2: S3-11.
2. Weisbord SD, Palevsky PM, (2005) Radiocontrast-induced acute renal failure. J Intensive Care Med 20: 63-75.
3. Nash K, Hafeez A, Hou S, (2002) Hospital-acquired renal insufficiency. Am J Kidney Dis 39: 930-936.
4. Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, et al. (2002) Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 40: 298-303.
5. Schultz MJ, Baas MC, van der Sluijs HP, Stamkot GA, Smit W, (2006) N-acetylcysteine and other preventive measures for contrast-induced nephropathy in the intensive care unit. Curr Med Chem 13: 2565-2570.
6. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, et al. (2002) Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105: 2259-2264.
7. Murphy SW, Barrett BJ, Parfrey PS, (2000) Contrast nephropathy. J Am Soc Nephrol 11: 177-182.
8. Shalansky SJ, Vu T, Pate GE, Levin A, Humphries KH, et al. (2005) N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best? Pharmacotherapy 25: 1095-1103.
9. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, et al. (2000) Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343: 180-184.
10. Stacul F, van der Molen A, Reimer P, Webb J, Thomsen H, et al. (2011) Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. 2527-2541.
11. Olsson B, Johansson M, Gabrielsson J, Bolme P, (1988) Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol 34: 77-82.
12. Borgstrom L, Kagedal B, Paulsen O, (1986) Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 31: 217-222.
13. Tsikas D, Sandmann J, Ikic M, Fauler J, Stichtenoth DO, et al. (1998) Analysis of cysteine and N-acetylcysteine in human plasma by high-performance liquid chromatography at the basal state and after oral administration of N-acetylcysteine. J Chromatogr B Biomed Sci Appl 708: 55-60.
14. Burgunder JM, Varriale A, Lauterburg BH, (1989) Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol 36: 127-131.
15. Shalansky SJ, Pate GE, Levin A, Webb JG, (2005) N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration. Heart 91: 997-999.
16. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, et al. (2003) A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 41: 2114-2118.
17. Carbonell N, Sanjuan R, Blasco M, Jorda A, Miguel A, (2010) N-acetylcysteine: short-term clinical benefits after coronary angiography in high-risk renal patients. Rev Esp Cardiol 63: 12-19.
18. Koc F, Ozdemir K, Kaya MG, Dogdu O, Vatankulu MA, et al. (2012) Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS-a multicenter prospective controlled trial. Int J Cardiol 155: 418-423.
19. Kefer JM, Hanet CE, Boitte S, Wilmotte L, De Kock M, (2003) Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient? Acta Cardiol 58: 555-560.
20. Rashid ST, Salman M, Myint F, Baker DM, Agarwal S, et al. (2004) Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg 40: 1136-1141.
21. Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, et al. (2004) A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 148: 422-429.
22. Carbonell N, Blasco M, Sanjuan R, Perez-Sancho E, Sanchis J, et al. (2007) Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial. Int J Cardiol 115: 57-62.
23. Poletti PA, Saudan P, Platon A, Mermillod B, Sautter AM, et al. (2007) I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. AJR Am J Roentgenol 189: 687-692.
24. Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, et al. (2010) Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol 55: 2201-2209.
25. Jaffery Z, Verma A, White CJ, Grant AG, Collins TJ, et al. (2012) A randomized trial of intravenous N-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes. Catheter Cardiovasc Interv 79: 921-926.
26. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
27. Molitoris BA, Levin A, Warnock DG, Joannidis M, Mehta RL, et al. (2007) Improving outcomes of acute kidney injury: report of an initiative. Nat Clin Pract Nephrol 3: 439-442.
28. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, et al. (1998) The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 51: 1235-1241.
29. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
30. Thompson SG, Sharp SJ, (1999) Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 18: 2693-2708.
31. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
32. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
33. Thompson SG, Higgins JP, (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21: 1559-1573.
34. Sterne JA, Egger M, Smith GD, (2001) Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ 323: 101-105.
35. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
36. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, et al. (2006) N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 354: 2773-2782.
37. Aslanger E, Uslu B, Akdeniz C, Polat N, Cizgici Y, et al. (2012) Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty. Coron Artery Dis 23: 265-270.
38. Ratcliffe JA, Thiagarajah P, Chen J, Kavala G, Kanei Y, et al. (2009) Prevention of contrast-induced nephropathy: A randomized controlled trial of sodium bicarbonate and N-acetylcysteine. Int J Angiol 18: 193-197.
39. Recio-Mayoral A, Chaparro M, Prado B, Cozar R, Mendez I, et al. (2007) The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol 49: 1283-1288.
40. Baranska-Kosakowska A, Zakliczynski M, Przybylski R, Zembala M, (2007) Role of N-acetylcysteine on renal function in patients after orthotopic heart transplantation undergoing coronary angiography. Transplant Proc 39: 2853-2855.
41. Briguori C, Airoldi F, D'Andrea D, Bonizzoni E, Morici N, et al. (2007) Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 115: 1211-1217.
42. Kotlyar E, Keogh AM, Thavapalachandran S, Allada CS, Sharp J, et al. (2005) Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures-a randomised controlled trial. Heart Lung Circ 14: 245-251.
43. Kiefer P, Vogt J, Radermacher P, (2000) From mucolytic to antioxidant and liver protection: new aspects in the intensive care unit career of N-acetylcysteine. Crit Care Med 28: 3935-3936.
44. Quintavalle C, Brenca M, De Micco F, Fiore D, Romano S, et al. (2011) In vivo and in vitro assessment of pathways involved in contrast media-induced renal cells apoptosis. Cell Death Dis 2: e155.
45. Heyman SN, Goldfarb M, Shina A, Karmeli F, Rosen S, (2003) N-acetylcysteine ameliorates renal microcirculation: studies in rats. Kidney Int 63: 634-641.
46. Weinbroum AA, Rudick V, Ben-Abraham R, Karchevski E, (2000) N-acetyl-L-cysteine for preventing lung reperfusion injury after liver ischemia-reperfusion: a possible dual protective mechanism in a dose-response study. Transplantation 69: 853-859.
47. DiMari J, Megyesi J, Udvarhelyi N, Price P, Davis R, et al. (1997) N-acetyl cysteine ameliorates ischemic renal failure. Am J Physiol 272: F292-298.
48. Hashimoto S, Gon Y, Matsumoto K, Takeshita I, Horie T, (2001) N-acetylcysteine attenuates TNF-alpha-induced p38 MAP kinase activation and p38 MAP kinase-mediated IL-8 production by human pulmonary vascular endothelial cells. Br J Pharmacol 132: 270-276.
49. Briguori C, Colombo A, Violante A, Balestrieri P, Manganelli F, et al. (2004) Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 25: 206-211.
50. Trivedi H, Daram S, Szabo A, Bartorelli AL, Marenzi G (2009) High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. Am J Med 122: 874 e879-815.
51. Hoffmann U, Fischereder M, Kruger B, Drobnik W, Kramer BK, (2004) The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 15: 407-410.
52. Haase M, Haase-Fielitz A, Ratnaike S, Reade MC, Bagshaw SM, et al. (2008) N-Acetylcysteine does not artifactually lower plasma creatinine concentration. Nephrol Dial Transplant 23: 1581-1587.
53. Moist L, Sontrop JM, Gallo K, Mainra R, Cutler M, et al. (2010) Effect of N-acetylcysteine on serum creatinine and kidney function: results of a randomized controlled trial. Am J Kidney Dis 56: 643-650.
54. Walser M, (1998) Assessing renal function from creatinine measurements in adults with chronic renal failure. Am J Kidney Dis 32: 23-31.
55. Brautigam M, Persson PB (2006) Do iodinated contrast media interfere with renal tubular creatinine secretion? Radiology 240: 615; author reply 615.
56. Ariarajah N, Gerstel E, Martin PY, Ponte B, (2011) [Biomarkers in acute kidney injury: an update]. Rev Med Suisse 7: 490-494.
57. Schmid CH, Stark PC, Berlin JA, Landais P, Lau J, (2004) Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. J Clin Epidemiol 57: 683-697.